Collapsing focal segmental glomerulosclerosis progression to kidney failure following combination therapy with pembrolizumab and enfortumab vedotin: a case report

Background Pembrolizumab (PB), a PD-1 immune checkpoint inhibitor, and enfortumab vedotin (EV), a Nectin-4 targeting antibody-drug conjugate delivering the microtubule-disrupting payload MMAE, represent the current standard of care for advanced urothelial carcinoma. While PB-associated glomerulopathy is a recognized rare complication, collapsing glomerulopathy with nephrotic-range proteinuria developing approximately five weeks after starting combination EV and PB, along with subsequent progression to kidney failure in a patient with advanced pre-existing chronic kidney disease (CKD) to our knowledge, has not been previously described. Case presentation A 76-year-old male with high-grade urothelial carcinoma and baseline CKD G4 (eGFR 25 mL/min/1.73 m 2 , creatinine 2.5 mg/dL, proteinuria 2.1 g/24 h), attributed to diabetes, hypertension, and prior cisplatin-based chemotherapy, was started on PB 200 mg IV and EV 1 mg/kg IV on a 21-day cycle. Approximately five weeks after starting therapy, he developed AKI presenting with a creatinine of 3.1 mg/dL, eGFR of 20 mL/min/1.73 m 2 , and nephrotic-range proteinuria of 13.1 g/24 hours. Both agents were discontinued, and empiric corticosteroids were given. Kidney biopsy then showed collapsing focal segmental glomerulosclerosis (cFSGS) in 20% of glomeruli, with 53% global glomerulosclerosis and 70% interstitial fibrosis and tubular atrophy. Kidney function did not improve with corticosteroids or subsequent rituximab. Eleven months after starting therapy, he required hemodialysis (creatinine 8.4 mg/dL, eGFR 6 mL/min/1.73 m²) and remains dialysis-dependent. Discussion/conclusion This case highlights three key teaching points. First, advanced pre-existing CKD may increase the risk of irreversible progression after cFSGS following ADC-immunotherapy, underscoring the need for baseline nephrology evaluation in this population. Second, the hypothesized interaction between pembrolizumab-associated podocyte dedifferentiation and MMAE-mediated cytotoxicity could help explain why this combination may be hazardous to a compromised kidney. This hypothesis, together with the possibility of an ADC payload class effect, warrants investigation as ADC-immunotherapy regimens are more widely adopted. Third, once advanced interstitial fibrosis is established, immunosuppressive salvage is unlikely to alter the trajectory, and its toxicity must be weighed against a low probability of benefit.

Authors

Institutions

Publication Details

Journal
BMC Nephrology
Published
2026-11-18
DOI
https://doi.org/10.1186/s12882-026-05519-3
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Collapsing focal segmental glomerulosclerosis progression to kidney failure following combination therapy with pembrolizumab and enfortumab vedotin: a case report

Caroline Gee, Ramy Magdy Hanna, Johnathan Zuckerman, George Hitti
3 links
BMC Nephrology
Renal Diseases and Glomerulopathies
article

Collapsing focal segmental glomerulosclerosis progression to kidney failure following combination therapy with pembrolizumab and enfortumab vedotin: a case report

Caroline Gee, Ramy Magdy Hanna, Johnathan Zuckerman, George Hitti
article en

Abstract

Background Pembrolizumab (PB), a PD-1 immune checkpoint inhibitor, and enfortumab vedotin (EV), a Nectin-4 targeting antibody-drug conjugate delivering the microtubule-disrupting payload MMAE, represent the current standard of care for advanced urothelial carcinoma. While PB-associated glomerulopathy is a recognized rare complication, collapsing glomerulopathy with nephrotic-range proteinuria developing approximately five weeks after starting combination EV and PB, along with subsequent progression to kidney failure in a patient with advanced pre-existing chronic kidney disease (CKD) to our knowledge, has not been previously described. Case presentation A 76-year-old male with high-grade urothelial carcinoma and baseline CKD G4 (eGFR 25 mL/min/1.73 m 2 , creatinine 2.5 mg/dL, proteinuria 2.1 g/24 h), attributed to diabetes, hypertension, and prior cisplatin-based chemotherapy, was started on PB 200 mg IV and EV 1 mg/kg IV on a 21-day cycle. Approximately five weeks after starting therapy, he developed AKI presenting with a creatinine of 3.1 mg/dL, eGFR of 20 mL/min/1.73 m 2 , and nephrotic-range proteinuria of 13.1 g/24 hours. Both agents were discontinued, and empiric corticosteroids were given. Kidney biopsy then showed collapsing focal segmental glomerulosclerosis (cFSGS) in 20% of glomeruli, with 53% global glomerulosclerosis and 70% interstitial fibrosis and tubular atrophy. Kidney function did not improve with corticosteroids or subsequent rituximab. Eleven months after starting therapy, he required hemodialysis (creatinine 8.4 mg/dL, eGFR 6 mL/min/1.73 m²) and remains dialysis-dependent. Discussion/conclusion This case highlights three key teaching points. First, advanced pre-existing CKD may increase the risk of irreversible progression after cFSGS following ADC-immunotherapy, underscoring the need for baseline nephrology evaluation in this population. Second, the hypothesized interaction between pembrolizumab-associated podocyte dedifferentiation and MMAE-mediated cytotoxicity could help explain why this combination may be hazardous to a compromised kidney. This hypothesis, together with the possibility of an ADC payload class effect, warrants investigation as ADC-immunotherapy regimens are more widely adopted. Third, once advanced interstitial fibrosis is established, immunosuppressive salvage is unlikely to alter the trajectory, and its toxicity must be weighed against a low probability of benefit.

BMC Nephrology
University of California, Los Angeles (US), University of California, Irvine (US)
University of California, Irvine
Good health and well-being
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon